BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25

• Press Releases

  Nabsys Announces First Publication Showcasing CRISPR/Cas9 Mediated Approach to Expand the Capabilities of Electronic Genome Mapping

  September 21, 2026

   · 

  4 min read
• Press Releases

  Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

  September 21, 2026

   · 

  20 min read
• Press Releases

  Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

  September 21, 2026

   · 

  5 min read
• Press Releases

  NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

  September 21, 2026

   · 

  9 min read
• Press Releases

  Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

  September 21, 2026

   · 

  1 min read
• Press Releases

  Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

  September 21, 2026

   · 

  6 min read
• Press Releases

  SELUTION SLR™ Drug-Eluting Balloon Approved by FDA for In-Stent Restenosis: First and Only Sirolimus Drug-Eluting Balloon in the US

  September 21, 2026

   · 

  3 min read
• Press Releases

  Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

  September 21, 2026

   · 

  4 min read
• Press Releases

  BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences

  The Company will provide an update on the clinical translation of its biomarker platform and showcase industry collaborations supporting scalable, high-throughput mass spectrometry.

  September 21, 2026

   · 

  4 min read
• 

  C-suite

  Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting

  Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.

  September 21, 2026

   · 

  5 min read

   · 

  Annalee Armstrong